Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.
REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of...
REDWOOD CITY, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of...
Advanced to Cohort 6 in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancersAbstract accepted for BDC-4182, a claudin 18.2-targeting BoltbodyTM ISAC at the...
BOLT SHAREHOLDER ALERT: Edelson Lechtzin LLP Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Shareholders to Consult Legal Counsel About the Pending Securities Fraud Class Action PR...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0136 | -2.125 | 0.64 | 0.677 | 0.6002 | 94986 | 0.63751011 | CS |
4 | -0.0116 | -1.81818181818 | 0.638 | 0.68 | 0.545 | 144172 | 0.62071051 | CS |
12 | -0.1095 | -14.879739095 | 0.7359 | 0.78 | 0.545 | 174289 | 0.67263836 | CS |
26 | -0.5136 | -45.0526315789 | 1.14 | 1.335 | 0.545 | 198316 | 0.76872734 | CS |
52 | -0.3836 | -37.9801980198 | 1.01 | 1.56 | 0.545 | 157742 | 0.90075837 | CS |
156 | -12.7536 | -95.3183856502 | 13.38 | 14.03 | 0.545 | 203858 | 2.24477769 | CS |
260 | -21.3636 | -97.1514324693 | 21.99 | 43.07 | 0.545 | 193525 | 6.78973937 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.